We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Clarifies Exposure Limits, Risk-Based Models for the Prevention of Contamination in Drug Manufacturing
EMA Clarifies Exposure Limits, Risk-Based Models for the Prevention of Contamination in Drug Manufacturing
The EMA is clarifying agency expectations on the implementation of risk-based models and exposure limits to prevent cross-contamination during manufacturing in a Q&A guideline, telling manufacturers that all products should have health-based exposure limits (HBEL).